^
    CANCER:

    Peritoneal Cancer





    Show legend
    Group by Gene:
    bevacizumab-tnjn
    bevacizumab-maly
    		0
    VEGF-A inhibitor
    bevacizumab-awwb
    Aybintio (bevacizumab biosimilar)
    bevacizumab
    bevacizumab-adcd
    1
    VEGF-A inhibitor, PARP inhibitor
    bevacizumab + olaparib
    bevacizumab + niraparib
    niraparib
    		2
    PARP inhibitor
    rucaparib
    olaparib
    pamiparib
    cisplatin + gemcitabine
    		3
    DNA synthesis inhibitor
    cisplatin
    gemcitabine
    anastrozole
    		4
    Aromatase inhibitor
    letrozole
    exemestane
    5
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    pegylated liposomal doxorubicin
    6
    Tubulin polymerization promoter, Bcl2 inhibitor, Tubulin inhibitor
    carboplatin + micellar paclitaxel
    carboplatin + albumin-bound paclitaxel
    7
    Topoisomerase I inhibitor
    topotecan
    irinotecan
    8
    Alkylating agent
    melphalan
    cyclophosphamide
    9
    GnRH agonist
    leuprolide acetate
    10
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + pegylated liposomal doxorubicin
    11
    Thymidylate synthase inhibitor
    capecitabine
    12
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    13
    Bifunctional alkylating agent, DNA synthesis inhibitor
    cisplatin + ifosfamide
    14
    Bifunctional alkylating agent, Tubulin polymerization promoter
    carboplatin + ifosfamide
    15
    Tubulin polymerization promoter
    carboplatin
    16
    Estrogen receptor antagonist
    tamoxifen
    17
    Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel
    paclitaxel
    18
    Progesterone receptor agonist
    megestrol
    19
    Multi-tyrosine kinase inhibitor
    pazopanib
    20
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    21
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    22
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    23
    Bifunctional alkylating agent
    ifosfamide
    24
    MEK inhibitor
    trametinib
    25
    Selective estrogen receptor degrader
    fulvestrant
    26
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    27
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    28
    VEGFR inhibitor, DLL4 inhibitor
    OMP-305B83
    29
    PD1 inhibitor
    pembrolizumab
    30
    PARP1 inhibitor
    BSI 201
    31
    RET inhibitor
    selpercatinib
    EP
    BEP
    		32
    Chemotherapy
    IP
    VAC
    CAPOX
    FOLFOX
    33
    Bifunctional alkylating agent, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + ifosfamide
    34
    Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel
    35
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    36
    VEGF-A inhibitor, Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    bevacizumab + mirvetuximab soravtansine-gynx
    37
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    38
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    39
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    40
    Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    STRO-002
    mirvetuximab soravtansine-gynx
    41
    VEGF-A inhibitor, Microtubule inhibitor
    bevacizumab + ixabepilone
    No biomarker
    FOLR1 expression
    FOLR1 positive
    HRD + BRCA1 mutation
    HRD + BRCA2 mutation
    BRCA2 mutation
    BRCA1 mutation
    NTRK3 fusion
    NTRK1 fusion
    MSI-H/dMMR
    HRD
    TMB-H
    RAD51C mutation
    PD-L1 expression
    NTRK2 fusion
    RET fusion
    TUBB3 expression